SARC-F Sarcopenia Screen
Also known as: SARC-F, SARC-F questionnaire, Strength Assistance Rising Climbing Falls screen
SARC-F is a brief, five-item self-report questionnaire for case-finding of sarcopenia — the age-related loss of skeletal muscle mass and function — in older adults. Introduced by Theodore Malmstrom and John Morley in 2013, its name is an acronym for the five domains it assesses: Strength, Assistance in walking, Rising from a chair, Climbing stairs, and Falls. Each item is scored 0 to 2, giving a total from 0 to 10, and a score of 4 or higher signals likely sarcopenia and risk of poor functional outcomes. Because it requires no equipment, no clinician, and under a minute to complete, SARC-F is recommended by major consensus groups (including the European and Asian sarcopenia working groups) as the first step in sarcopenia case-finding, to be confirmed by muscle-strength and mass measurement.
Key highlights
- Extremely fast (under a minute), self-administered, and requires no equipment, enabling screening at scale.
- Endorsed by major consensus groups (EWGSOP2, AWGS) as the recommended entry point for sarcopenia case-finding.
- Graded 0–2 scoring across five clinically meaningful domains gives a simple, interpretable severity gradient.
- Predicts poor functional outcomes, supporting its use to target confirmatory testing and intervention.
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use SARC-F as the first step in sarcopenia case-finding in any setting — primary care, hospital, community survey — where you need a fast, equipment-free way to decide who should undergo confirmatory muscle testing. It is recommended by the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Asian Working Group for Sarcopenia as the screening entry point in their diagnostic algorithms. It suits older adults capable of self-report and is ideal for high-volume or resource-limited contexts. It is less appropriate as a stand-alone diagnosis (it must be confirmed by strength and mass measures), in cognitively impaired patients without an informant, or when high sensitivity is required, since its modest sensitivity means a negative SARC-F does not exclude early sarcopenia.
Strengths & limitations
- Extremely fast (under a minute), self-administered, and requires no equipment, enabling screening at scale.
- Endorsed by major consensus groups (EWGSOP2, AWGS) as the recommended entry point for sarcopenia case-finding.
- Graded 0–2 scoring across five clinically meaningful domains gives a simple, interpretable severity gradient.
- Predicts poor functional outcomes, supporting its use to target confirmatory testing and intervention.
- Modest sensitivity means it misses milder or early sarcopenia, so a negative screen does not rule it out.
- It is a functional symptom score, not a measure of muscle mass or strength, and cannot diagnose sarcopenia alone.
- Self-report is unreliable in people with cognitive impairment without an informant.
- Performance varies across populations and reference standards, so cutoff behavior should be checked locally.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What does the SARC-F acronym stand for?
It stands for the five domains assessed: Strength (difficulty lifting/carrying about ten pounds), Assistance in walking (difficulty walking across a room), Rising from a chair (difficulty transferring), Climbing stairs (difficulty with a flight of ten steps), and Falls (number in the past year). The first four are scored 0–2 by degree of difficulty and the last by fall frequency, summing to a 0–10 total in which higher scores indicate greater impairment.
Can SARC-F diagnose sarcopenia on its own?
No. SARC-F is a case-finding screen, not a diagnosis. A score of 4 or higher flags likely sarcopenia and prompts confirmatory assessment — measuring muscle strength (such as grip strength or a chair-stand test) and, where available, muscle mass via DXA or bioimpedance — following consensus algorithms like EWGSOP2 and AWGS. Its strength is identifying who needs those confirmatory tests quickly and without equipment.
Why is SARC-F's sensitivity considered low?
Validation studies show SARC-F is more specific than sensitive: it reliably identifies people with established functional impairment but misses milder or early sarcopenia, where everyday tasks are not yet noticeably difficult. This is an intentional trade-off for a quick self-report sieve, but it means a negative SARC-F should not be taken to exclude sarcopenia when clinical suspicion is high; in such cases proceed directly to muscle-function testing.
Sources
- 1.Malmstrom, T. K., & Morley, J. E. (2013). SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. Journal of the American Medical Directors Association, 14(8), 531-532.
- 2.Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016). SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. Journal of Cachexia, Sarcopenia and Muscle, 7(1), 28-36.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 23). SARC-F Sarcopenia Screen. ScholarGate. https://scholargate.app/social-gerontology/sarc-f-sarcopenia-screening